Answers are grounded in this paper and cite their sources.
Pharmaceutical marketing is being reshaped by the growing use of digital technologies and artificial intelligence (AI) in communication, customer engagement, and commercial decision-making. Promotion that once relied almost entirely on medical representatives, face-to-face physician visits, product detailing, and printed material is now supplemented, and in some cases reshaped, by digital platforms, social media, e-detailing, webinars, data analytics, and omnichannel communication. This review looks at how AI is being applied to pharmaceutical digital marketing, with particular attention to machine learning, predictive analytics, segmentation of customers and healthcare professionals, personalized communication, customer relationship management, generative AI, and omnichannel engagement. Evidence from the published literature suggests that digital channels widen the reach and flexibility of pharmaceutical communication, while AI adds the ability to analyse large datasets, anticipate behaviour, segment audiences, and personalize content at scale. At the same time, this shift brings its own set of problems: data privacy, inconsistent data quality, algorithmic bias, the risk of misinformation, limited transparency, regulatory compliance, and the continued need for human oversight all surface repeatedly in the literature. Empirical studies also indicate that digital engagement can shape how healthcare professionals are communicated with, influence prescribing-related behaviour, and affect consumer attitudes, though the size of this effect depends heavily on the channel, audience, and therapeutic area involved. Taken together, the evidence points toward a future in which human expertise, digital communication, and AI-supported decision-making work alongside one another rather than one replacing the other. For this model to be sustainable, pharmaceutical marketing will need to be built on responsible implementation, ethical communication, evidence-based content, and clear governance.
No takes yet. Share an insight, caveat, or question.
Aaditya Suryakant Asware1*, Yash Milind Dhamale1, Shraddha H. Dingare2, Dr. Meera Deshmukh (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: